Plasma Sample Clauses

Plasma. Proteins

Plasma wall studies, exploring plasma-wall interaction scenarios with Li coating and Li-liquid limiter concepts.

Plasma wall interaction and divertor physics;

Plasma. (a) Cerus and BHC acknowledge and agree that the Cooperative Development Work, as defined in the RBC/FFP Agreement, for the Plasma System; (i) continues with respect to activities directed toward obtaining CE Xxxx in the European Territory; (ii) is terminated, effective January 1, 2005, with respect to activities directed to North America; (b) With respect to activities directed toward obtaining CE Xxxx for the Plasma System and related manufacturing and validation, Baxter agrees, at Cerus’ request and expense, to carry out the further development activities set forth on Exhibit C to this Agreement within the time schedules set forth on such Exhibit for such activities. The charge for such activities will not exceed the amount set forth on such Exhibit, provided that the scope of such activities is not expanded. Cerus agrees to fund those Baxter activities, as well as Cerus activities, directed toward completing the application for CE Xxxx, including through funding from the Escrow Account pursuant to Section 2.8, above. (c) With respect to the countries of the BioOne Territory, it is acknowledged that Cerus has been discussing with BioOne and Baxter a potential transaction related to the Plasma System that is similar to the transaction previously EXECUTION 10 RESTRUCTURING AND SETTLEMENT AGREEMENT [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. entered into for the Platelet System. In the event such a transaction is entered into, it is anticipated that development and commercialization will be carried on by BioOne. Pending the completion of the transactions, the Parties do not expect that any Cooperative Development work will be funded specifically directed to the countries of the BioOne Territory. The parties agree to cooperate to supply information to BioOne and engage in discussions with BioOne to facilitate the completion of such transaction. Such activities will not be considered Cooperative Development work that is subject to funding under the RBC/FFP Agreement. In the event that such transaction is not entered into with BioOne or another entity within [ * ] months of the date of this Agreement, the Cooperative Development Work for the Plasma System will be considered terminated with respect to the countries of the BioOne Territory. (d) With respect to ac...

Plasma. Proteins Figure 1 shows the relative position of most of the plasma proteins.

Plasma accelerating structures, as they shall be further developed in this work, define the frontier in high gradient acceleration and therefore address this important challenge. The May 2014 Particle Physics Project Prioritization Panel (P5) report on “Building for Discovery – Strategic Plan for U.S. Particle Physics in the Global Context” identifies the “critical need for technical breakthroughs that will yield more cost-effective accelerators. For example, ultra-high gradient accelerator techniques will require the development of power sources …, and accelerating structures (plasmas, metallic, and dielectric) that can sustain high average power, have high damage threshold, and can be cascaded.” As introduced above, proof-of-principle measurements for GeV-class plasma acceleration have been published in high-ranking journals and the physics principles are proven. The science communities have assessed plasma acceleration and have confirmed its potential, as seen in the quotes above. Issues and problems are known, are predominantly of technical nature and requirements for improvements have been listed. The EuroNNAc2 network pursues the approach that user beam quality for plasma accelerators can be achieved with adequate resources and a combined effort from experts in different laboratories with a large range of expert competences. No fundamental issue that prevents these objectives is known today. It can be seen from Figure 1 that there are many institutes in Europe involved in advanced accelerator research and that there are 16 major research facilities operating or under construction in Europe. A coordinated strategy is required for creating a “combined effort” as mentioned above. The AWAKE experiment is developing proton beams as new and hopefully highly efficient power sources for plasma accelerators. The high stored power in a single proton bunch should allow driving electrons with a single or few acceleration stages to high beam energy. This is required for a particle physics collider. The EuPRAXIA project aims at using the available power source technology of modern lasers as of today and will not address limitations in the power source, except stability. We appreciate that laser efficiency and repetition rate are important issues for high power applications like plasma linear colliders, requiring R&D and significant improvements. There are several Horizon 2020 proposals for the Future Emerging Technology (FET) program on the subject of innovative laser po...

Plasma. The term "Plasma" as used in connection with the Initial Products, Frozen Formulation or Improved Product means plasma sourced from the United States packaged and delivered in accordance with the specifications described on Exhibit I.

Plasma. Serum............................................................ Tissue............................................................ Urine............................................................. Other.............................................................. Animal Yes No .............................................................................. .............................................................................. Microorganism Yes No .............................................................................. .............................................................................. other Yes No .............................................................................. ..............................................................................

Plasma. Specification The specification for the Plasma set out in Schedule 5 and all applicable legal and regulatory requirements. Product VITIGAM IVIG, an immunoglobulin manufactured from the Plasma using BPL’s proprietary GAMMAPLEX process. Product Specification The specification for the Product set out in Schedule 3 as varied from time- to-time by agreement between the parties. Regulatory Approval All approvals (including without limitation, supplements, amendments, pre- and post-approvals), licenses, registrations or authorisations by the applicable regulatory authority necessary for manufacturing, distribution and sale in the Territory of the Product. Royalties The royalties on the sales of the Products in the Territory as set out in Schedule 2. Royalty Period The “Royalty Period” is for a period of [ * ] years commencing on [ * ]. Royalty Rate [ * ]% of Net Sales (as defined) Service Fee The fees for the Services as set out in Schedule 2 and any fee for other services provided by BPL as agreed in writing by the parties. Services Stability testing, technical and scientific data, technical advice and support to Client in relation to clinical trials of the Product and obtaining the necessary licences for the sale of the Product in the Territory as detailed in Schedule 1. Term An initial period commencing on the Commencement Date and ending [ * ] years after the date of US Food and Drug Administration (“FDA”) approval of the Product for sale in the United States of America (the “Initial Period”) and additional renewal periods each of [ * ] years’ duration (“Renewal Periods”), unless terminated by either party serving on the other no less than [ * ] months’ written notice of termination (such notice to take effect at the end of the Initial Period or a Renewal Period (as the case may be)) or otherwise terminated in accordance with the terms of this Agreement. Schedule 1 The Services Schedule 2 The Fees and Payment Schedule 3 Product Specification Schedule 4 Trade Marks Schedule 5 Donor Centres and Plasma Specification Schedule 6 Additional Terms and Conditions Schedule 7 BPL’s Standard Terms and Conditions for Contract Manufacture SIGNED by the parties or their duly authorised representatives on [ ] 20[ ] Name: Signature: Position: Date: Name: Signature: Position: Date: 1 All Services be performed in the English language. 2 The Services shall include:

Plasma. Upon execution of this Settlement Agreement, the right, title ------ and interest in the Plasma shall pass from Bayer to Vitex; provided, however, that Vitex shall provide Bayer with any proceeds from its sale of the Plasma in the same manner as insurance proceeds are treated pursuant to Section 1(b) hereof.